These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19089915)

  • 21. Cytotoxic synergism of methioninase in combination with 5-fluorouracil and folinic acid.
    Machover D; Zittoun J; Broët P; Metzger G; Orrico M; Goldschmidt E; Schilf A; Tonetti C; Tan Y; Delmas-Marsalet B; Luccioni C; Falissard B; Hoffman RM
    Biochem Pharmacol; 2001 Apr; 61(7):867-76. PubMed ID: 11274973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective Metabolic Targeting of Human Osteosarcoma Cells
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Murakami T; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Hoffman RM
    Anticancer Res; 2017 Sep; 37(9):4807-4812. PubMed ID: 28870899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey.
    Hoffman RM
    Expert Opin Biol Ther; 2015 Jan; 15(1):21-31. PubMed ID: 25439528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
    Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
    Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overcoming High Trabectedin Resistance of Soft-tissue Sarcoma With Recombinant Methioninase: A Potential Solution of a Recalcitrant Clinical Problem.
    Morinaga S; Han Q; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
    Anticancer Res; 2024 Sep; 44(9):3785-3791. PubMed ID: 39197928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma.
    Higuchi T; Oshiro H; Miyake K; Sugisawa N; Han Q; Tan Y; Park J; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Chawla SP; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4653-4657. PubMed ID: 31519563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model.
    Sugisawa N; Hamada K; Han Q; Yamamoto J; Sun YU; Nishino H; Kawaguchi K; Bouvet M; Unno M; Hoffman RM
    Anticancer Res; 2020 Sep; 40(9):4869-4874. PubMed ID: 32878774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Sugisawa N; Higuchi T; Han Q; Hozumi C; Yamamoto J; Tashiro Y; Nishino H; Kawaguchi K; Bouvet M; Murata T; Unno M; Hoffman RM
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):61-67. PubMed ID: 33768300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polyethylene glycol conjugation of recombinant methioninase for cancer therapy.
    Tan Y; Sun X; Xu M; An Z; Tan X; Han Q; Miljkovic DA; Yang M; Hoffman RM
    Protein Expr Purif; 1998 Feb; 12(1):45-52. PubMed ID: 9473456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma.
    Igarashi K; Kawaguchi K; Li S; Han Q; Tan Y; Murakami T; Kiyuna T; Miyake K; Miyake M; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Singh SR; Eilber FC; Hoffman RM
    Cancer Lett; 2018 Mar; 417():168-173. PubMed ID: 29306021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Toxicity of Recombinant Methioninase and Polyethylene Glycol (PEG) Recombinant Methioninase in Primates.
    Hoffman RM; Yang Z; Tan Y; Han Q; Li S; Yagi S
    Methods Mol Biol; 2019; 1866():211-229. PubMed ID: 30725418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methioninase Gene Therapy.
    Hoffman RM; Miki K; Al-Refaie W; Xu M; Tan Y
    Methods Mol Biol; 2019; 1866():173-197. PubMed ID: 30725416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma.
    Morinaga S; Han Q; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
    Anticancer Res; 2024 Sep; 44(9):3777-3783. PubMed ID: 39197933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective Synergy of Rapamycin Combined With Methioninase on Cancer Cells Compared to Normal Cells.
    Ardjmand D; Kubota Y; Sato M; Han Q; Mizuta K; Morinaga S; Hoffman RM
    Anticancer Res; 2024 Mar; 44(3):929-933. PubMed ID: 38423628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral-recombinant Methioninase in Combination With Rapamycin Eradicates Osteosarcoma of the Breast in a Patient-derived Orthotopic Xenograft Mouse Model.
    Masaki N; Han Q; Samonte C; Wu NF; Hozumi C; Wu J; Obara K; Kubota Y; Aoki Y; Bouvet M; Hoffman RM
    Anticancer Res; 2022 Nov; 42(11):5217-5222. PubMed ID: 36288875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple-Methyl Blockade With Recombinant Methioninase, Cycloleucine, and Azacitidine Arrests a Pancreatic Cancer Patient-Derived Orthotopic Xenograft Model.
    Sugisawa N; Yamamoto J; Han Q; Tan Y; Tashiro Y; Nishino H; Inubushi S; Hamada K; Kawaguchi K; Unno M; Bouvet M; Hoffman RM
    Pancreas; 2021 Jan; 50(1):93-98. PubMed ID: 33370029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Broad selective efficacy of rMETase and PEG-rMETase on cancer cells in vitro.
    Tan Y; Xu M; Hoffman RM
    Anticancer Res; 2010 Mar; 30(3):793-8. PubMed ID: 20392998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
    Aoki Y; Tome Y; Wu NF; Yamamoto J; Hamada K; Han Q; Bouvet M; Nishida K; Hoffman RM
    Anticancer Res; 2021 Apr; 41(4):1745-1751. PubMed ID: 33813378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model.
    Yamamoto J; Miyake K; Han Q; Tan Y; Inubushi S; Sugisawa N; Higuchi T; Tashiro Y; Nishino H; Homma Y; Matsuyama R; Chawla SP; Bouvet M; Singh SR; Endo I; Hoffman RM
    Cancer Lett; 2020 Nov; 492():174-184. PubMed ID: 32739322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methioninase Cell-Cycle Trap Cancer Chemotherapy.
    Hoffman RM; Yano S; Igarashi K
    Methods Mol Biol; 2019; 1866():133-148. PubMed ID: 30725413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.